GLSI vs RAIL Comparison

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

FreightCar America Inc is a manufacturer of railcars and components, serving diverse transportation needs in North America. The company designs and produces a wide range of railcar types, including box cars, hoppers, covered hoppers, gondolas, and flat cars for both intermodal and non-intermodal freight. The company has two segments: The Manufacturing segment encompasses new railcar manufacturing, used railcar sales, leasing, and rebuilds, while the Aftermarket segment includes the selling of forged, cast and fabricated railcar parts and supplies for all railcar types, and provides aftermarket services including safety training, railcar inspections, and preventative maintenance. The company's revenue is predominantly derived from its Manufacturing segment.